Care cascade structural intervention versus standard of care in the diagnosis and treatment of HIV in China: a cluster-randomized controlled trial protocol.
BACKGROUND
The high rate of attrition along the care cascade of infection with human immunodeficiency virus (HIV) results in lost opportunities to provide timely antiretroviral therapy (ART) and to prevent unnecessarily high mortality. This study aims to assess the effectiveness of a structural intervention, the one-stop ("One4All") strategy that streamlines China's HIV care cascade with the intent to improve testing completeness, ART initiation, viral suppression, and mortality.


METHOD
A two-arm, cluster-randomized controlled trial was implemented in twelve county hospitals in Guangxi China to test the effectiveness of the One4All strategy (intervention arm) compared to the current standard of care (SOC; control arm). The twelve study hospitals were selected for homogeneity and allocated one-to-one to the intervention and control arms. All patients screening HIV positive in study hospitals were enrolled. Target study enrollment was 180 participants per arm, 30 participants per hospital. Basic demographic information was collected as well as HIV risk behavior and route of infection. In intervention hospitals, patients then went on to receive point-of-care CD4 testing and in-parallel viral load (VL) testing whereas patients in control hospitals progressed through the usual SOC cascade. The primary outcome measure was testing completeness within 30 days of positive initial HIV screening result. Testing completeness was defined as receipt of all tests, test results, and post-test counseling. The secondary outcome measure was ART initiation (receipt of first ART prescriptions) within 90 days of positive initial HIV screening result. Tertiary outcome measures were viral suppression (≤200 copies/mL) and all-cause mortality at 12 months.


DISCUSSION
We expect that this first-ever, cluster-randomized controlled trial of a bundle of interventions intended to streamline the HIV care cascade in China (the One4All strategy) will provide strong evidence for the benefit of accelerating diagnosis, thorough clinical assessment, and ART initiation via an optimized HIV care cascade. We furthermore anticipate that this evidence will be valuable to policymakers looking to elevate China's overall HIV/AIDS response to meet the UNAIDS 90-90-90 targets and the broader, global goal of eradication of the HIV/AIDS epidemic.


TRIAL REGISTRATION
ClinicalTrials.gov # NCT02084316 . (Registered on March 7, 2014).
['Mao|Yurong|Y|', 'Wu|Zunyou|Z|', 'McGoogan|Jennifer M|JM|', 'Liu|David|D|', 'Gu|Diane|D|', 'Erinoff|Lynda|L|', 'Ling|Walter|W|', 'VanVeldhuisen|Paul|P|', 'Detels|Roger|R|', 'Hasson|Albert L|AL|', 'Lindblad|Robert|R|', 'Montaner|Julio S G|JSG|', 'Tang|Zhenzhu|Z|', 'Zhao|Yan|Y|']
D000328:Adult D002681:China D002985:Clinical Protocols D016000:Cluster Analysis D003376:Counseling D005260:Female D015658:HIV Infections D006679:HIV Seropositivity D006761:Hospitals D006801:Humans D019095:Point-of-Care Systems D000067716:Point-of-Care Testing D059039:Standard of Care
Antiretroviral therapy Mortality HIV care cascade Viral suppression Point-of-care Viral load CD4 count HIV continuum of care HIV test Linkage to care